IPOs
Filter News
Found 17,195 articles
-
Continuing 2024’s biotech initial public offering rally, Boundless Bio will debut Thursday on the Nasdaq with the proceeds used to advance its pipeline of extrachromosomal DNA cancer assets.
-
Boundless Bio Announces Pricing of Initial Public Offering
3/27/2024
Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of $16.00 per share.
-
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
3/25/2024
Allarity Therapeutics, Inc. today announced that the Company has been granted a formal extension until April 24, 2024 to regain compliance under Nasdaq Listing Rules 5550(a)(2) (the “Bid Price Rule”) and 5550(b)(1) (the “Equity Rule”) or any of the alternative requirements in Listing Rule 5550(b).
-
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
3/25/2024
Aquestive Therapeutics, Inc. today announced the closing of its previously announced underwritten public offering of 16,666,667 shares of its common stock at the public offering price of $4.50 per share.
-
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
3/22/2024
Sangamo Therapeutics, Inc. today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase and sale of an aggregate of 24,761,905 shares of its common stock.
-
XOMA Declares Quarterly Preferred Stock Dividends - March 21, 2024
3/21/2024
XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.
-
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/20/2024
Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors approved certain equity awards to the Company’s new President and Chief Executive Officer, Steven Lo, effective March 18, 2024.
-
Delcath Systems Closes $7 Million Private Placement
3/20/2024
Delcath Systems, Inc. confirmed the closing of the previously announced private placement with certain accredited investors comprised of existing investors.
-
Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023
3/20/2024
Lifecore Biomedical, Inc. announced today that it has filed its Annual Report on Form 10-K for the fiscal year ended May 28, 2023 (“FY23”) with the United States Securities and Exchange Commission (the “SEC”).
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - March 20, 2024
3/20/2024
BridgeBio Pharma, Inc. today announced that on March 16, 2024, the compensation committee of BridgeBio’s board of directors approved equity grants to 16 new employees in restricted stock units for an aggregate of 71,146 shares of the Company’s common stock, with the effective date of March 18, 2024.
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - March 19, 2024
3/19/2024
Schrödinger, Inc. today reported that on March 15, 2024, the company granted (i) non-statutory stock options to purchase 40,400 shares of the company’s common stock to six newly hired employees and (ii) restricted stock units (RSUs) with respect to 18,550 shares of the company’s common stock to eight newly hired employees.
-
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
3/19/2024
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants.
-
Gemina Announces Closing of $910,000 Convertible Note Financing
3/19/2024
Gemina Laboratories Ltd. is pleased to announce that further to its news release dated February 22, 2024, it has raised gross proceeds of $910,000 under its non-brokered private placement of unsecured convertible notes of the Company.
-
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
3/19/2024
Fate Therapeutics, Inc. today announced the pricing of an underwritten offering of 14,545,454 shares of its common stock at an offering price of $5.50 per share.
-
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
3/19/2024
Genprex, Inc. today announced that it has entered into definitive agreements for the sale and issuance of 1,542,112 shares of common stock.
-
Contineum Therapeutics joined the 2024 initial public offering class on Friday with an SEC filing. The biotech will use the IPO proceeds to complete a Phase II trial for its most mature candidate targeting multiple sclerosis.
-
Elicio Therapeutics Announces $6.0 Million Private Placement Financing
3/18/2024
Elicio Therapeutics, Inc. announced today that it has entered into a subscription agreement to sell pre-funded warrants to purchase up to 1,032,702 shares of its common stock at a purchase price of $5.81 per pre-funded warrant.
-
Spyre Therapeutics Announces $180 Million Private Placement - March 18, 2024
3/18/2024
Spyre Therapeutics, Inc. today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $180 million to the Company, before deducting placement agent fees and offering expenses.
-
Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock
3/18/2024
Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares of its Series B Convertible Preferred Stock (the “Series B Preferred”) for shares of common stock pursuant to an agreement with stockholders affiliated with Viking Global Investors (“Viking”) and Casdin Capital (“Casdin").
-
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders
3/18/2024
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company") today Announced that its Board of Directors (Board) has authorized its Chairman and management to take all necessary steps to affect a Dividend of HOPE Therapeutics.